Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
March 02 2023 - 7:00AM
Matinas BioPharma (NYSE American: MTNB), a clinical-stage
biopharmaceutical company focused on delivering groundbreaking
therapies using its lipid nanocrystal (LNC) platform delivery
technology to maximize global clinical impact and patient access,
announces that MAT2203, an oral LNC formulation of amphotericin B
(AMB), will be featured in two oral presentations at the 33rd
European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID). The hybrid in-person and virtual Congress is
being held April 15-18 in Copenhagen and the MAT2203 presentations
will both take place on April 18.
The two presentations are as follows:
- “All-oral lipid nanocrystal
amphotericin B for cryptococcal meningitis: a phase II randomized
trial” will be presented by David Boulware, MD, MPH, Professor of
Medicine at the University of Minnesota and Principal Investigator
for the Phase 2 EnACT trial evaluating MAT2203 in cryptococcal
meningitis.
- “Calcaneal Rhodotorula mucilaginosa
osteomyelitis treated with oral amphotericin B (MAT2203)” - Senior
Author, Marisa H. Miceli, MD, Professor of Medicine, Specializing
in Fungal Infections and Transplant Diseases, Division of
Infectious Diseases, Internal Medicine, at the University of
Michigan.
“We are delighted that clinical evidence
supporting the ability of MAT2203 to safely and effectively improve
outcomes for patients suffering from potentially deadly fungal
infections will be presented at this prestigious conference,” said
Theresa Matkovits, PhD, Chief Development Officer of Matinas
BioPharma. “The efficacy of amphotericin B is well established, but
this fungicidal drug is typically administered selectively only to
patients with severe disease because of its toxicity, which
significantly limits its use. MAT2203 reduces systemic toxicity by
directing amphotericin B to targeted cells at sites of infection,
supporting a favorable safety profile relative to IV-administered
AMB with the additional benefit of oral administration. The data to
be presented at ECCMID, from both our EnACT Phase 2 trial and a
compelling compassionate use case, support our strategy of
developing the ideal antifungal agent for the treatment of a
variety of invasive fungal infections while also potentially having
a dramatic pharmacoeconomic impact on the cost of treating these
deadly diseases.
“Importantly, success with MAT2203 gives us
confidence that our platform technology can be applied beyond small
molecules to a multitude of treatment modalities that alter the
genetic mechanisms that underlie disease, an area we view as the
future of medicine,” added Dr. Matkovits. “We believe that our
delivery platform holds promise for the targeted delivery of gene
therapy, providing Matinas with the opportunity to develop robust
internal and partnered drug development candidates.”
About MAT2203Matina BioPharma
is developing MAT2203 as a potential oral broad-spectrum treatment
for invasive deadly fungal infections. Although amphotericin B is a
fungicidal agent, it is currently only available through an
intravenous route of administration, which is known to be
associated with a number of significant safety issues such as renal
toxicity and anemia due to very high circulating levels of
amphotericin B. MAT2203 has the potential to overcome the
significant limitations of the currently available amphotericin B
products due to its targeted oral delivery, combining comparable
fungicidal activity with targeted delivery resulting in a lower
risk of toxicity and potentially creating the ideal antifungal
agent for the treatment of invasive fungal infections.
About ECCMID The European
Congress of Clinical Microbiology & Infectious Diseases
(ECCMID) has become one of the most comprehensive and influential
congresses in the field of infectious diseases and an exciting
networking opportunity, bringing together more than 14,000
colleagues from all over the world. The scientific program is built
by the ECCMID Programme Committee, an independent group of experts
representing all disciplines related to clinical microbiology,
infectious diseases, infection control and prevention, and public
health.
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its lipid nanocrystal (LNC) platform
delivery technology to maximize global clinical impact and patient
access. The Company is developing its own internal portfolio of
products as well as partnering with leading pharmaceutical
companies to develop novel formulations that capitalize on the
unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated
that this novel technology can provide solutions to many of the
challenges in achieving safe and effective intracellular delivery
for both small molecules and larger, more complex molecules such as
mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The
combination of a unique mechanism of action and flexibility with
formulation and route of administration (including oral) positions
Matinas’ LNC technology potentially to become the preferred
next-generation intracellular drug delivery vehicle with distinct
advantages over both lipid nanoparticles and viral vectors. For
more information, please visit www.matinasbiopharma.com.
Forward-looking StatementsThis
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
those relating to our business activities, our strategy and plans,
our collaborations with National Resilience, Inc. and BioNTech SE,
the potential of our LNC platform delivery technology, and the
future development of its product candidates, the Company’s ability
to identify and pursue development, licensing and partnership
opportunities for its products or platform delivery technology on
favorable terms, if at all, and the ability to obtain required
regulatory approval and other statements that are predictive in
nature, that depend upon or refer to future events or conditions.
All statements other than statements of historical fact are
statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor Contact
LHA Investor RelationsJody Cain
Jcain@lhai.com310-691-7100
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jan 2025 to Feb 2025
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Feb 2024 to Feb 2025